Completed PHASE2 INTERVENTIONAL 2-arm NCT00869791

A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa

Sponsor: Impax Laboratories, LLC

Updated 12 times since 2017 Last updated: Oct 25, 2019 Started: Nov 30, 2008 Primary completion: Jun 30, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Parkinson's Disease, this trial is completed. The trial is conducted by Impax Laboratories, LLC and has accumulated 12 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

12 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Dec 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 7 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Dec 2019 — Jan 2021 [monthly]

Completed PHASE2
Jul 2019 — Dec 2019 [monthly]

Completed PHASE2
Jun 2018 — Jul 2019 [monthly]

Completed PHASE2
May 2017 — Jun 2018 [monthly]

Completed PHASE2

Phase: PHASE1_PHASE2 → PHASE2
Feb 2017 — May 2017 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Impax Laboratories, LLC

Data source: Impax Laboratories, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hayward, United States